Use of piperazine compound in combination with radiotherapy for treatment of tumor
Patent Information
- Application Number
- MYPI2025000889
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-08-09
- Filing Date
- 2023-07-31
- Publication Date
- 2024-02-09
AI Technical Summary
The response of patients with malignant tumors to radioactive therapy varies greatly. Some patients cannot benefit from long-term treatment, and some patients even worsen. It is difficult for existing technology to effectively improve the effect of tumor treatment.
A piperazine compound is used in combination with radiotherapy to improve the anti-tumor effect of radiotherapy by providing a general formula compound or its pharmaceutically acceptable salt, stereoisomer or deuterated product as an active ingredient. This compound has high selectivity and significant inhibitory activity on PARP7, and can significantly improve the therapeutic effect of radiotherapy.
After the compound is combined with radiotherapy, the anti-tumor effect is significantly improved, has good safety and tolerability, and synergistically enhances the therapeutic effect, especially in non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and hormone receptor-positive It has shown excellent efficacy in the treatment of breast cancer and other types of tumors.
Smart Images

Figure PI2025000889_DRAWING_001
Abstract
Description
Use of piperazine compounds in combined radiotherapy for the treatment of tumors Technical Field
[0001] The present application relates to the use of a piperazine compound in combined radiotherapy for treating tumors. Background Art
[0002] Radiotherapy is an important modality in the comprehensive treatment of malignant tumors. Neoadjuvant therapy based on conventional long-term radiotherapy has become the standard treatment for a variety of malignant tumors. However, long-term clinical studies have found that the response of patients with malignant tumors to radiotherapy varies greatly. Although some patients can achieve complete pathological remission at the end of the treatment cycle, some patients do not benefit from long-term treatment, and a small number of patients even experience worsening of the disease. Therefore, it is of great clinical significance to improve the therapeutic effect of tumors by combining small molecule anti-tumor compounds with radiotherapy.
[0003] Summary of the Invention
[0004] The applicant's PCT application PCT / CN2022 / 094124 describes the use of a piperazine derivative in the preparation of a medicament for treating cancer. The compound described in the specification exhibits high selectivity and significant inhibitory activity against PARP7. Subsequent studies unexpectedly discovered that the piperazine derivative can significantly enhance the anti-tumor effect of radiotherapy.
[0005] Therefore, the present invention provides a use of a piperazine compound in combined radiotherapy for treating tumors.
[0006] One or more embodiments of the present invention provide the use of a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof as an active ingredient for combined radiotherapy for treating tumors:
[0007] in:
[0008] X1 is NH, O or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O;
[0009] X2 is O or a single bond;
[0010] X3 and X4 are each independently C or N;
[0011] R 1a 、R 1b Each independently is H, D or C 1-6 Alkyl; or R 1a 、R 1b Together with the carbon atom to which it is attached, it forms a 3- to 5-membered cycloalkyl group;
[0012] R 2a 、R2b Each independently is H, D or C 1-6 Alkyl; or R 2a 、R 2b Together with the carbon atom to which it is attached, it forms a 3- to 5-membered cycloalkyl group;
[0013] R3 is H, D, C 1-6 Alkyl, halogen or cyano, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0014] R4 and R5 are each independently H, D or C 1-6 Alkyl; or R4, R5 and the connected carbon atom form a 3 to 5-membered cycloalkyl;
[0015] R6 and R7 are each independently H, D or C 1-6 Alkyl; or R6, R7 and the connected carbon atom form C=O;
[0016] R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8, R9 and the carbon atom to which they are connected form C=O; or R8 and R9 and the carbon atom to which they are connected form a 3- to 5-membered cycloalkyl;
[0017] R 10 Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, CONR 10a R 10b , halogen, cyano, S(O)2R 10c SR 10d or a 3 to 5-membered cycloalkyl group, the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens;
[0018] R 10a 、R 10b 、R 10c 、R 10d Each independently is H, D or C 1-6 alkyl;
[0019] A is R a C 1-6 Alkyl, C 3-5 Cycloalkyl, halogen or cyano, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0020] B is a 5- to 10-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S;
[0021] C is a 5- to 6-membered heterocyclic ring containing 1 to 3 N heteroatoms;
[0022] m is 1, 2, or 3;
[0023] n is 0, 1, 2, or 3;
[0024] p is 0, 1, 2 or 3.
[0025] One or more embodiments of the present invention provide the use of a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, or deuterated form thereof as an active ingredient for treating tumors in combination with radiotherapy, wherein: X1 is NH, O, or a 4- to 6-membered heterocycle containing 1 to 3 heteroatoms selected from N and O;
[0026] X2 is O or a single bond;
[0027] X3 and X4 are each independently C or N;
[0028] R 1a 、R 1b Each independently is H, D or C 1-6 alkyl;
[0029] R 2a 、R 2b Each independently is H, D or C 1-6 Alkyl; or R 2a 、R 2b Together with the carbon atom to which it is attached, it forms a 3- to 5-membered cycloalkyl group;
[0030] R3 is H, D, C 1-6 Alkyl, halogen or cyano, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0031] R4 and R5 are each independently H, D or C 1-6 Alkyl; or R4, R5 and the connected carbon atom form a 3 to 5 membered cycloalkyl;
[0032] R6 and R7 are each independently H, D or C 1-6 alkyl;
[0033] R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8, R9 and the connected carbon atom form C=O;
[0034] R 10 Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, CONR 10a R 10b , halogen, cyano, S(O)2R 10c SR 10d or a 3 to 5-membered cycloalkyl group, the C1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens;
[0035] R 10a 、R 10b 、R 10c 、R 10d Each independently is H, D or C 1-6 alkyl;
[0036] A is R a C 1-6 Alkyl, C 3-5 Cycloalkyl, halogen or cyano, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0037] B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S;
[0038] C is a 5- to 6-membered heterocyclic ring containing 1 to 3 N heteroatoms;
[0039] m is 1, 2, or 3;
[0040] n is 0, 1, 2, or 3;
[0041] p is 0, 1, 2 or 3.
[0042] One or more embodiments of the present invention provide the use of a compound of formula (I-1) or a pharmaceutically acceptable salt, stereoisomer, or deuterated form thereof as an active ingredient for combined radiotherapy for treating tumors:
[0043] in:
[0044] X1 is NH or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O;
[0045] X2 is 0;
[0046] X3 and X4 are each independently C or N;
[0047] R 1a 、R 1b Each independently is H, D or C 1-6 alkyl;
[0048] R 2a 、R 2b Each independently is H, D or C 1-6 alkyl;
[0049] R3 is H, D, C 1-6 Alkyl or halogen, the C1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0050] R4 and R5 are each independently H, D or C 1-6 alkyl;
[0051] R6 and R7 are each independently H, D or C 1-6 alkyl;
[0052] R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8 and R9 form C=O with the carbon atom to which they are connected;
[0053] R 10 C 1-6 Alkyl, C 1-6 Alkoxy, cyano or SR 10d , the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens;
[0054] R 10d H, D or C 1-6 alkyl;
[0055] A is
[0056] B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S;
[0057] C is a 5- to 6-membered heterocyclic ring containing 1 to 3 N heteroatoms;
[0058] m is 1, 2, or 3;
[0059] n is 0, 1, 2 or 3.
[0060] One or more embodiments of the present invention provide the use of a compound of formula (I-2) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof as an active ingredient for combined radiotherapy for treating tumors:
[0061] in:
[0062] X1 is NH;
[0063] X2 is 0;
[0064] R 1a 、R 1b Each independently is H, D or C 1-6 alkyl;
[0065] R 2a 、R 2b Each independently is H, D or C1-6 alkyl;
[0066] R3 is H, D, C 1-6 Alkyl or halogen, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0067] R4 and R5 are each independently H, D or C 1-6 alkyl;
[0068] R6 and R7 are each independently H, D or C 1-6 alkyl;
[0069] R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8 and R9 and the carbon atom to which they are attached form C=O;
[0070] R 10 C 1-6 Alkyl, C 1-6 Alkoxy, cyano or SR 10d , the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens;
[0071] R 10d H, D or C 1-6 alkyl;
[0072] A is
[0073] B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S;
[0074] m is 1, 2, or 3;
[0075] n is 0, 1, 2 or 3.
[0076] One or more embodiments of the present invention provide the use of a compound of formula (I-2) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof as an active ingredient for treating tumors in combination with radiotherapy, wherein: X1 is NH;
[0077] X2 is 0;
[0078] R 1a 、R 1b Each independently is H, D or C 1-6 alkyl;
[0079] R 2a 、R 2b Each independently is H, D or C 1-6 alkyl;
[0080] R3 is H, D, C 1-6 Alkyl or halogen, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0081] R4 and R5 are each independently H, D or C 1-6 alkyl;
[0082] R6 and R7 are each independently H, D or C 1-6 alkyl;
[0083] R8 and R9 are each independently H, D or C 1-6 Alkyl, or R8 and R9 form C=O with the carbon atom to which they are connected;
[0084] R 10 C 1-6 Alkyl, cyano, or SR 10d , the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0085] R 10d H, D or C 1-6 alkyl;
[0086] A is
[0087] B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S;
[0088] m is 1, 2, or 3;
[0089] n is 0, 1, 2 or 3.
[0090] One or more embodiments of the present invention provide the use of a compound of formula (I-2) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof as an active ingredient for treating tumors in combination with radiotherapy, wherein: X1 is selected from NH;
[0091] X2 is selected from O;
[0092] R 1a 、R 1b Each independently selected from H, D or C 1-6 alkyl;
[0093] R 2a 、R 2b Each independently selected from H, D or C 1-6 alkyl;
[0094] R3 is H, D, C 1-6 Alkyl or halogen, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0095] R4 and R5 are each independently H or D;
[0096] R6 and R7 are each independently H or D;
[0097] R8 and R9 are each independently H or D;
[0098] R 10 CF3 or SR 10d ;
[0099] R 10d H, D or C 1-6 alkyl;
[0100] A is
[0101] B is
[0102] m is 1, 2, or 3;
[0103] n is 0, 1, 2 or 3.
[0104] One or more embodiments of the present invention provide the use of a compound of formula (I-2) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof as an active ingredient for treating tumors in combination with radiotherapy, wherein: X1 is selected from NH;
[0105] X2 is selected from O;
[0106] R 1a 、R 1b Each independently selected from H, D or C 1-3 alkyl;
[0107] R 2a 、R 2b Each independently selected from H, D or C 1-3 alkyl;
[0108] R3 is selected from H, D or CF3;
[0109] R4 and R5 are each independently selected from H or D;
[0110] R6 and R7 are each independently selected from H or D;
[0111] R8 and R9 are each independently selected from H or D;
[0112] R 10 is CF3;
[0113] A is
[0114] B is
[0115] m is 1, 2, or 3;
[0116] n is 0, 1 or 2.
[0117] One or more embodiments of the present invention provide the use of a compound of formula (I-3) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof as an active ingredient for combined radiotherapy for treating tumors:
[0118] in:
[0119] X1 is NH or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O;
[0120] X2 is 0;
[0121] R 1a 、R 1b Each independently is H, D or C 1-6 alkyl;
[0122] R 2a 、R 2b Each independently is H, D or C 1-6 alkyl;
[0123] R4 and R5 are each independently H, D or C 1-6 alkyl;
[0124] R6 and R7 are each independently H, D or C 1-6 alkyl;
[0125] R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8, R9 and the connected carbon atom form C=O;
[0126] R 10 C 1-6 Alkyl, C 1-6 Alkoxy, cyano or SR 10d , the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens;
[0127] R 10d H, D or C 1-6 alkyl;
[0128] A is
[0129] B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S;
[0130] m is 1, 2, or 3;
[0131] n is 0, 1, 2 or 3.
[0132] One or more embodiments of the present invention provide the use of a compound of formula (I-3) or a pharmaceutically acceptable salt, stereoisomer, or deuterated form thereof as an active ingredient for combined radiotherapy for treating tumors, wherein:
[0133] X1 is NH or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O;
[0134] X2 is 0;
[0135] R 1a 、R 1b Each independently is H, D or C 1-3 alkyl;
[0136] R 2a 、R 2b Each independently is H, D or C 1-3 alkyl;
[0137] R4 and R5 are each independently H, D or C 1-3 alkyl;
[0138] R6 and R7 are each independently H, D or C 1-3 alkyl;
[0139] R8 and R9 are each independently H, D or C 1-3 Alkyl; or R8 and R9 form C=O with the carbon atom to which they are connected;
[0140] R 10 C 1-6 Alkyl, cyano or SR 10d , the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens;
[0141] R 10d H, D or C 1-6 alkyl;
[0142] A is
[0143] B is
[0144] m is 1, 2, or 3;
[0145] n is 0, 1 or 2.
[0146] One or more embodiments of the present invention provide the use of a compound of formula (I-3) or a pharmaceutically acceptable salt, stereoisomer, or deuterated form thereof as an active ingredient for combined radiotherapy for treating tumors, wherein:
[0147] X1 is NH;
[0148] X2 is 0;
[0149] R 1a 、R 1b Each independently is H, D or C 1-3 alkyl;
[0150] R 2a 、R 2b Each independently is H or D;
[0151] R4 and R5 are each independently H or D;
[0152] R6 and R7 are each independently H or D;
[0153] R8 and R9 are each independently H or D;
[0154] R 10 is CF3;
[0155] A is
[0156] B is
[0157] m is 1, 2, or 3;
[0158] n is 0, 1 or 2.
[0159] In one or more embodiments of the present invention, the active ingredient is selected from the following compounds or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof:
[0160] In one or more embodiments of the present application, the active ingredient has a synergistic effect when used in combination with radiotherapy.
[0161] In one or more embodiments of the present application, the active ingredient is contained in a pharmaceutical composition, and the pharmaceutical composition further contains one or more pharmaceutically acceptable excipients, diluents or carriers.
[0162] In one or more embodiments of the present application, the total daily dose of the active ingredient is selected from 50-1500 mg, preferably 100-1000 mg, more preferably 400-800 mg, measured as the amount of free base.
[0163] In one or more embodiments of the present application, the active ingredient and radiotherapy are administered simultaneously.
[0164] In one or more embodiments of the present application, the active ingredient and radiotherapy are administered sequentially, for example, the active ingredient is administered first and then radiotherapy, or radiotherapy is administered first and then the active ingredient. The administration interval can be several hours, days, weeks or months.
[0165] In one or more embodiments of the present application, the active ingredient is administered orally, with a dosage frequency of three times a day, twice a day, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once every four weeks, preferably twice a day or once a day.
[0166] In one or more embodiments of the present application, the tumor is selected from solid tumors.
[0167] In one or more embodiments of the present application, the solid tumor is selected from non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, hormone receptor-positive (HR+) breast cancer, PARP7 amplified advanced solid tumors, colon cancer or lung cancer, preferably colon cancer or lung cancer, more preferably colon cancer.
[0168] Advantages of the present invention
[0169] The anti-tumor effect of compound ① combined with radiotherapy was significantly better than that of radiotherapy alone, and it also had good safety and tolerability, indicating that the active ingredient of the present invention has a significant synergistic effect when combined with radiotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0170] Figure 1 is the structural formula of compound ①.
[0171] FIG2 shows the tumor volume growth curve of tumor-bearing mice.
[0172] Figure 3 shows the body weight change rate of tumor-bearing mice. DETAILED DESCRIPTION
[0173] The following describes in detail the implementation process of the present invention and the beneficial effects produced by specific embodiments, which is intended to help readers better understand the essence and characteristics of the present invention and is not intended to limit the scope of implementation of this case.
[0174] The present invention is described in further detail below with reference to the accompanying drawings:
[0175] Compound ① in the embodiment is compound 1 of PCT application PCT / CN2022 / 094124, and compound ① was prepared according to its preparation method.
[0176] Drug efficacy test in CT26 mouse tumor model
[0177] 1. Experimental steps
[0178] 1.1 Cell culture
[0179] Colon cancer cells CT26 were purchased from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in a cell culture incubator containing 5% CO 2 . When the cells reached the exponential growth phase, they were trypsinized, harvested, counted, and plated.
[0180] 1.2 Construction of subcutaneous transplanted tumors
[0181] Female BALB / c mice were selected and tumor cells were injected subcutaneously to establish a CT26 subcutaneous xenograft tumor model. 3 Thirty-two animals were screened and divided into four groups based on tumor size using the S-shaped grouping method: blank group, compound ① group, irradiation group, and compound ① plus irradiation group, with 8 animals in each group. Grouping was designated as experimental day 0 (PG-D0). Each irradiation group received a 2 Gy irradiation dose for 5 consecutive days starting on D1. Compound ① (125 mpk, BID) was administered starting on day 1 (D1).
[0182] 2. Determination method
[0183] 2.1 Tumor volume
[0184] The tumor diameter was measured with a vernier caliper twice a week, the tumor volume was calculated, and the tumor growth curve was drawn. The calculation formula for tumor volume (V) was:
[0185] V=1 / 2×a×b 2 , where a and b represent the long diameter and short diameter of the tumor, respectively.
[0186] 2.2 Mouse weight
[0187] During the drug treatment period, the mice were weighed at least twice a week.
[0188] 3. Experimental results
[0189] As shown in Figures 2 and 3, the anti-tumor effect of compound ① combined with radiotherapy is significantly better than that of radiotherapy alone, and it also has good safety and tolerability. This shows that the active ingredient of the present invention has a significant synergistic effect when combined with radiotherapy.
[0190] The specification of the present invention describes the specific implementation scheme in detail. Those skilled in the art should recognize that the above implementation scheme is exemplary and cannot be understood as limiting the present invention. For those skilled in the art, without departing from the principles of the present invention, by making several improvements and modifications to the present invention, the technical solutions obtained by these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. Use of a compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer or deuterated product thereof as an active ingredient for combined radiotherapy for treating tumors: in: X1 is NH, O or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O; X2 is O or a single bond; X3 and X4 are each independently C or N; R 1a 、R 1b Each independently is H, D or C 1-6 Alkyl; or R 1a 、R 1b Together with the carbon atom to which it is attached, it forms a 3- to 5-membered cycloalkyl group; R 2a 、R 2b Each independently is H, D or C 1-6 Alkyl; or R 2a 、R 2b Together with the carbon atom to which it is attached, it forms a 3- to 5-membered cycloalkyl group; R3 is H, D, C 1-6 Alkyl, halogen or cyano, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; R4 and R5 are each independently H, D or C 1-6 Alkyl; or R4, R5 and the connected carbon atom form a 3 to 5-membered cycloalkyl; R6 and R7 are each independently H, D or C 1-6 Alkyl; or R6, R7 and the connected carbon atom form C=O; R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8, R9 and the carbon atom to which they are connected form C=O; or R8 and R9 and the carbon atom to which they are connected form a 3- to 5-membered cycloalkyl; R 10 Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, CONR 10a R 10b , halogen, cyano, S(O)2R 10c SR 10d or a 3 to 5-membered cycloalkyl group, the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens; R 10a 、R 10b 、R 10c 、R 10d Each independently is H, D or C 1-6 alkyl; A is R a C 1-6 Alkyl, C 3-5 Cycloalkyl, halogen or cyano, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; B is a 5- to 10-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S; C is a 5- to 6-membered heterocyclic ring containing 1 to 3 N heteroatoms; m is 1, 2, or 3; n is 0, 1, 2, or 3; p is 0, 1, 2 or 3.
2. The use according to claim 1, characterized in that: The active ingredient is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof, wherein: X1 is NH, O or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O; X2 is O or a single bond; X3 and X4 are each independently C or N; R 1a 、R 1b Each independently is H, D or C 1-6 alkyl; R 2a 、R 2b Each independently is H, D or C 1-6 Alkyl; or R 2a 、R 2b Together with the carbon atom to which it is attached, it forms a 3- to 5-membered cycloalkyl group; R3 is H, D, C 1-6 Alkyl, halogen or cyano, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; R4 and R5 are each independently H, D or C 1-6 Alkyl; or R4, R5 and the connected carbon atom form a 3 to 5-membered cycloalkyl; R6 and R7 are each independently H, D or C 1-6 alkyl; R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8, R9 and the connected carbon atom form C=O; R 10 Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, CONR 10a R 10b , halogen, cyano, S(O)2R 10c SR 10d or a 3 to 5-membered cycloalkyl group, the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens; R 10a 、R 10b 、R 10c 、R 10d Each independently is H, D or C 1-6 alkyl; A is R a C 1-6 Alkyl, C 3-5 Cycloalkyl, halogen or cyano, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S; C is a 5- to 6-membered heterocyclic ring containing 1 to 3 N heteroatoms; m is 1, 2, or 3; n is 0, 1, 2, or 3; p is 0, 1, 2 or 3.
3. The use according to claim 2, characterized in that: The active ingredient is a compound represented by formula (I-1) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof, wherein: in: X1 is NH or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O; X2 is 0; X3 and X4 are each independently C or N; R 1a 、R 1b Each independently is H, D or C 1-6 alkyl; R 2a 、R 2b Each independently is H, D or C 1-6 alkyl; R3 is H, D, C 1-6 Alkyl or halogen, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; R4 and R5 are each independently H, D or C 1-6 alkyl; R6 and R7 are each independently H, D or C 1-6 alkyl; R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8 and R9 form C=O with the carbon atom to which they are connected; R 10 C 1-6 Alkyl, C 1-6 Alkoxy, cyano or SR 10d , the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens; R 10d H, D or C 1-6 alkyl; A is B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S; C is a 5- to 6-membered heterocyclic ring containing 1 to 3 N heteroatoms; m is 1, 2, or 3; n is 0, 1, 2 or 3.
4. The use according to claim 3, characterized in that: The active ingredient is a compound represented by formula (I-2) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof, wherein: in: X1 is NH; X2 is 0; R 1a 、R 1b Each independently is H, D or C 1-6 alkyl; R 2a 、R 2b Each independently is H, D or C 1-6 alkyl; R3 is H, D, C 1-6 Alkyl or halogen, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; R4 and R5 are each independently H, D or C 1-6 alkyl; R6 and R7 are each independently H, D or C 1-6 alkyl; R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8 and R9 and the carbon atom to which they are attached form C=O; R 10 C 1-6 Alkyl, C 1-6 Alkoxy, cyano or SR 10d , the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens; R 10d H, D or C 1-6 alkyl; A is B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S; m is 1, 2, or 3; n is 0, 1, 2 or 3.
5. The use according to claim 4, characterized in that: The active ingredient is a compound represented by formula (I-2) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof, wherein: X1 is NH; X2 is 0; R 1a 、R 1b Each independently is H, D or C 1-6 alkyl; R 2a 、R 2b Each independently is H, D or C 1-6 alkyl; R3 is H, D, C 1-6 Alkyl or halogen, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; R4 and R5 are each independently H, D or C 1-6 alkyl; R6 and R7 are each independently H, D or C 1-6 alkyl; R8 and R9 are each independently H, D or C 1-6 Alkyl, or R8 and R9 form C=O with the carbon atom to which they are connected; R 10 C 1-6 Alkyl, cyano, or SR 10d , the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; R 10d H, D or C 1-6 alkyl; A is B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S; m is 1, 2, or 3; n is 0, 1, 2 or 3.
6. The use according to claim 5, characterized in that: The active ingredient is a compound represented by formula (I-2) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof, wherein: X1 is selected from NH; X2 is selected from O; R 1a 、R 1b Each independently selected from H, D or C 1-6 alkyl; R 2a 、R 2b Each independently selected from H, D or C 1-6 alkyl; R3 is H, D, C 1-6 Alkyl or halogen, the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; R4 and R5 are each independently H or D; R6 and R7 are each independently H or D; R8 and R9 are each independently H or D; R 10 CF3 or SR 10d ; R 10d H, D or C 1-6 alkyl; A is B is m is 1, 2, or 3; n is 0, 1, 2 or 3.
7. The use according to claim 6, characterized in that: The active ingredient is a compound represented by formula (I-2) or a pharmaceutically acceptable salt, stereoisomer or deuterated substance thereof, wherein: X1 is selected from NH; X2 is selected from O; R 1a 、R 1b Each independently selected from H, D or C 1-3 alkyl; R 2a 、R 2b Each independently selected from H, D or C 1-3 alkyl; R3 is selected from H, D or CF3; R4 and R5 are each independently selected from H or D; R6 and R7 are each independently selected from H or D; R8 and R9 are each independently selected from H or D; R 10 is CF3; A is B is m is 1, 2, or 3; n is 0, 1 or 2.
8. The use according to claim 1, characterized in that: The active ingredient is a compound represented by formula (I-3) or a pharmaceutically acceptable salt, stereoisomer or deuterated product thereof, wherein: in: X1 is NH or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O; X2 is 0; R 1a 、R 1b Each independently is H, D or C 1-6 alkyl; R 2a 、R 2b Each independently is H, D or C 1-6 alkyl; R4 and R5 are each independently H, D or C 1-6 alkyl; R6 and R7 are each independently H, D or C 1-6 alkyl; R8 and R9 are each independently H, D or C 1-6 Alkyl; or R8, R9 and the connected carbon atom form C=O; R 10 C 1-6 Alkyl, C 1-6 Alkoxy, cyano or SR 10d , the C 1-6 Alkyl, C 1-6 Alkoxy is optionally substituted with 1 to 3 halogens; R 10d H, D or C 1-6 alkyl; A is B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S; m is 1, 2, or 3; n is 0, 1, 2 or 3.
9. The use according to claim 8, characterized in that: The active ingredient is a compound represented by formula (I-3) or a pharmaceutically acceptable salt, stereoisomer or deuterated product thereof, wherein: X1 is NH or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O; X2 is 0; R 1a 、R 1b Each independently is H, D or C 1-3 alkyl; R 2a 、R 2b Each independently is H, D or C 1-3 alkyl; R4 and R5 are each independently H, D or C 1-3 alkyl; R6 and R7 are each independently H, D or C 1-3 alkyl; R8 and R9 are each independently H, D or C 1-3 Alkyl; or R8 and R9 form C=O with the carbon atom to which they are connected; R 10 C 1-6 Alkyl, cyano or SR 10d , the C 1-6 The alkyl group is optionally substituted with 1 to 3 halogens; R 10d H, D or C 1-6 alkyl; A is B is m is 1, 2, or 3; n is 0, 1 or 2.
10. The use according to claim 9, characterized in that: The active ingredient is a compound represented by formula (I-3) or a pharmaceutically acceptable salt, stereoisomer or deuterated product thereof, wherein: X1 is NH; X2 is 0; R 1a 、R 1b Each independently is H, D or C 1-3 alkyl; R 2a 、R 2b Each independently is H or D; R4 and R5 are each independently H or D; R6 and R7 are each independently H or D; R8 and R9 are each independently H or D; R 10 is CF3; A is B is m is 1, 2, or 3; n is 0, 1 or 2.
11. The use according to any one of claims 1 to 10, characterized in that: The active ingredient is selected from the following compounds or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof:
12. The use according to any one of claims 1 to 11, characterized in that: The active ingredient is contained in a pharmaceutical composition, which also contains one or more pharmaceutically acceptable excipients, diluents or carriers.
13. The use according to any one of claims 1 to 12, characterized in that: The total daily dose of the active ingredient is selected from 50-1500 mg, preferably 100-1000 mg, more preferably 400-800 mg, measured as the free base.
14. The use according to any one of claims 1 to 13, characterized in that: The active ingredient and radiation therapy are administered simultaneously.
15. The use according to any one of claims 1 to 13, characterized in that: The active ingredient and radiation therapy are administered sequentially.
16. The use according to any one of claims 1 to 15, characterized in that: The active ingredient is administered orally, with a dosage frequency of twice a day or once a day.
17. The use according to any one of claims 1 to 16, characterized in that The tumor is selected from solid tumors.
